Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pembrolizumab when given
together with docetaxel or gemcitabine hydrochloride in treating patients with previously
treated urothelial cancer that has spread to other places in the body and usually cannot be
cured or controlled with treatment (advanced) or that has spread from the primary site (place
where it started) to other places in the body (metastatic). Monoclonal antibodies, such as
pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs
used in chemotherapy, such as docetaxel and gemcitabine hydrochloride, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving pembrolizumab together with docetaxel or
gemcitabine hydrochloride may be a better treatment for urothelial cancer.